(PRWEB) May 07, 2013
The birth control risk center at DrugRisk.com is announcing updated information on the site for women using Bayer’s contraceptive device Mirena. The company is launching a new, permanent birth control called Essure as an alternative to Mirena after purchasing the product’s maker*.
DrugRisk is designed to improve the safety of patients using popular medication devices, such as IUD contraceptives, by providing the latest product news, safety alerts, research and legal news. Patients can determine if others are experiencing similar side effects and decide if they need legal advice.
The resource center has learned Bayer recently purchased drug maker Conceptus, Inc. to obtain the rights to produce the Essure birth control device*. The small, flexible coil device is implanted into the fallopian tubes and works by creating a natural barrier in the tubes to prevent pregnancy*.
DrugRisk notes the move comes as Bayer’s other long-term contraceptive, Mirena, faces health risk warnings from experts. A study published by the Journal of the Society of Laparoendoscopic Surgeons warns patients about migration and perforation of Mirena IUDs after implantation**.
A study from the American Journal of Obstetrics and Gynecology also noted risks for women who must undergo surgery to remove an IUD like Mirena after the devices dislodge and perforate into the abdominal cavity***.
With a growing number of patients filing a Mirena lawsuit, federal cases have been consolidated to a special multi-district litigation court in the Southern District of New York (In Re: Mirena IUD Products Liability Litigation, MDL No. 2434).
Anyone who suffered perforation or required surgery while using a Mirena IUD is urged to speak with a lawyer about their legal rights. Due to the specialized nature of federal MDL drug injury cases, DrugRisk only recommends lawyers who are already handling Mirena lawsuits.
*Investor's Business Daily, 4/29/13; news.investors.com/business/042913-653882-bayer-buys-birth-control-device-maker-conceptus.htm
**JSLS, 3/15/11; ncbi.nlm.nih.gov/pmc/articles/PMC3134688/
***AJOG, 3/4/13; ajog.org/article/S0002-9378%2813%2900236-6/abstract